View ValuationAnterogen.Co.Ltd 将来の成長Future 基準チェック /06現在、 Anterogen.Co.Ltdの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長21.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • Jul 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.New Risk • Jul 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩150.4b (US$99.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.分析記事 • May 30We're Not Very Worried About Anterogen.Co.Ltd's (KOSDAQ:065660) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...お知らせ • Feb 25Anterogen.Co.,Ltd., Annual General Meeting, Mar 20, 2026Anterogen.Co.,Ltd., Annual General Meeting, Mar 20, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 65, magokjungang 2-ro, gangseo-gu, seoul South KoreaNew Risk • Dec 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Revenue is less than US$5m (₩7.3b revenue, or US$5.0m).分析記事 • Dec 01We're Hopeful That Anterogen.Co.Ltd (KOSDAQ:065660) Will Use Its Cash WiselyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...New Risk • Jul 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.お知らせ • Feb 21Anterogen.Co.,Ltd., Annual General Meeting, Mar 21, 2025Anterogen.Co.,Ltd., Annual General Meeting, Mar 21, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 65, magokjungang 2-ro, gangseo-gu, seoul South KoreaNew Risk • Feb 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (₩7.0b revenue, or US$4.7m).お知らせ • Jan 23Anterogen.Co.,Ltd. announced that it expects to receive KRW 5.0000314 billion in fundingAnterogen.Co.,Ltd. announced a private placement of 274,727 common shares at a price of KRW 18,200 for gross proceeds of KRW 5,000,031,400 on January 23, 2025. The transaction includes participation from Horizon Flowkai Venture Fund subscribed for 241,759 shares and Horizon Flow No. 1 PEF subscribed for 32,968 shares. The transaction has been approved by the board of directors of the company. The payment date of the transaction is January 31, 2025. The transaction is subject to lockup for one year from the date of deposit. The company will issue shares of par value of KRW 500 per share through third party allocation capital increase method.New Risk • Nov 14New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩140.4b (US$100.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.6% per year over the past 5 years. Minor Risks Revenue is less than US$5m (₩6.7b revenue, or US$4.7m). Market cap is less than US$100m (₩140.4b market cap, or US$100.0m).New Risk • Aug 05New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩130.4b (US$95.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.4% per year over the past 5 years. Minor Risks Revenue is less than US$5m (₩6.5b revenue, or US$4.8m). Market cap is less than US$100m (₩130.4b market cap, or US$95.6m).New Risk • Apr 17New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩137.4b (US$99.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.9% average weekly change). Revenue is less than US$5m (₩6.5b revenue, or US$4.7m). Market cap is less than US$100m (₩137.4b market cap, or US$99.3m).分析記事 • Apr 04Does Anterogen.Co.Ltd (KOSDAQ:065660) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...New Risk • Apr 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Revenue is less than US$5m (₩6.5b revenue, or US$4.8m).New Risk • Feb 05New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩132.3b (US$99.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Revenue is less than US$5m (₩6.3b revenue, or US$4.7m). Market cap is less than US$100m (₩132.3b market cap, or US$99.4m).New Risk • Oct 06New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩131.3b (US$97.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risks Revenue is less than US$5m (₩6.2b revenue, or US$4.6m). Market cap is less than US$100m (₩131.3b market cap, or US$97.5m).Reported Earnings • May 16First quarter 2023 earnings released: EPS: ₩4.00 (vs ₩273 loss in 1Q 2022)First quarter 2023 results: EPS: ₩4.00 (up from ₩273 loss in 1Q 2022). Net income: ₩37.4m (up ₩2.65b from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 03Full year 2022 earnings released: ₩706 loss per share (vs ₩59.00 loss in FY 2021)Full year 2022 results: ₩706 loss per share (further deteriorated from ₩59.00 loss in FY 2021). Net loss: ₩6.84b (loss widened ₩6.28b from FY 2021). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 16Third quarter 2022 earnings released: ₩155 loss per share (vs ₩43.00 loss in 3Q 2021)Third quarter 2022 results: ₩155 loss per share (further deteriorated from ₩43.00 loss in 3Q 2021). Net loss: ₩1.51b (loss widened 274% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.お知らせ • Mar 09Anterogen.Co.,Ltd. announced that it has received KRW 16 billion in funding from Shinhan Venture Investment Co, Ltd., NH Investment & Securities Co., Ltd., Investment Arm, SL InvestmentOn March 8, 2021, Anterogen.Co.,Ltd. (KOSDAQ:A065660) closed the transaction. The company issued round 5 unregistered unguaranteed unsecured convertible bonds.お知らせ • Feb 09Anterogen.Co.,Ltd., Annual General Meeting, Mar 19, 2021Anterogen.Co.,Ltd., Annual General Meeting, Mar 19, 2021, at 09:00 Korea Standard Time.分析記事 • Feb 05Health Check: How Prudently Does Anterogen.Co.Ltd (KOSDAQ:065660) Use Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Is New 90 Day High Low • Dec 20New 90-day high: ₩55,200The company is up 4.0% from its price of ₩53,300 on 21 September 2020. The South Korean market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 7.0% over the same period.分析記事 • Dec 14Does Anterogen.Co.Ltd's (KOSDAQ:065660) Share Price Gain of 25% Match Its Business Performance?It hasn't been the best quarter for Anterogen.Co.,Ltd. ( KOSDAQ:065660 ) shareholders, since the share price has fallen...Reported Earnings • Nov 18Third quarter 2020 earnings released: EPS ₩110Third quarter 2020 results: Net income: ₩983.9m (up ₩1.46b from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 87% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Oct 22New 90-day low: ₩46,550The company is down 30% from its price of ₩66,800 on 24 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 10.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Anterogen.Co.Ltd は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測KOSDAQ:A065660 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20268,057-1,557-1,515-1,250N/A12/31/20257,536-1,374-1,286-1,020N/A9/30/20257,321-1,911-1,150-820N/A6/30/20257,181-1,992-2,327-1,948N/A3/31/20257,003-2,420-1,634-1,218N/A12/31/20246,933-2,293-1,172-860N/A9/30/20246,953-1,441-628-333N/A6/30/20246,659-2,314-317-9N/A3/31/20246,490-3,450-2,081-1,948N/A12/31/20236,500-2,841-2,191-1,988N/A9/30/20236,288-3,228-3,429-3,197N/A6/30/20236,233-3,703-2,450-2,160N/A3/31/20236,467-4,192-1,715-1,039N/A12/31/20226,591-6,837-3,456-1,975N/A9/30/20227,538-6,452-4,334-2,363N/A6/30/20227,793-5,347-4,787-2,388N/A3/31/20228,304-347-5,568-3,545N/A12/31/20218,122-554-6,040-3,045N/A9/30/20216,585-1,339-8,316-4,201N/A6/30/20215,87349-8,895-5,185N/A3/31/20214,732-6,226-10,096-3,477N/A12/31/20204,151-4,375-10,151-4,415N/A9/30/20204,177-6,705-8,109-3,948N/A6/30/20204,169-8,165-9,013-3,282N/A3/31/20204,065-4,186-6,821-3,447N/A12/31/20194,148-4,050N/A-1,649N/A9/30/20193,9071,093N/A1,359N/A6/30/20193,661359N/A-1,089N/A3/31/20193,560-1,522N/A-939N/A12/31/20183,607-962N/A-1,505N/A9/30/20183,765-3,030N/A-2,375N/A6/30/20184,328-1,451N/A-363N/A3/31/20184,446-448N/A-778N/A12/31/20175,357447N/A379N/A9/30/20175,284163N/A2,453N/A6/30/20175,066-103N/A1,676N/A3/31/20174,757-154N/A-131N/A12/31/20164,896372N/A-131N/A9/30/20164,813871N/A-1,024N/A6/30/20165,0011,348N/A257N/A3/31/20164,9861,337N/A1,773N/A12/31/20153,532-58N/A844N/A9/30/20153,241-491N/A-504N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A065660の予測収益成長が 貯蓄率 ( 3.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A065660の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A065660の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A065660の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A065660の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A065660の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/13 18:43終値2026/07/13 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Anterogen.Co.,Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Jul 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
New Risk • Jul 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩150.4b (US$99.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.
分析記事 • May 30We're Not Very Worried About Anterogen.Co.Ltd's (KOSDAQ:065660) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
お知らせ • Feb 25Anterogen.Co.,Ltd., Annual General Meeting, Mar 20, 2026Anterogen.Co.,Ltd., Annual General Meeting, Mar 20, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 65, magokjungang 2-ro, gangseo-gu, seoul South Korea
New Risk • Dec 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Revenue is less than US$5m (₩7.3b revenue, or US$5.0m).
分析記事 • Dec 01We're Hopeful That Anterogen.Co.Ltd (KOSDAQ:065660) Will Use Its Cash WiselyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
New Risk • Jul 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
お知らせ • Feb 21Anterogen.Co.,Ltd., Annual General Meeting, Mar 21, 2025Anterogen.Co.,Ltd., Annual General Meeting, Mar 21, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 65, magokjungang 2-ro, gangseo-gu, seoul South Korea
New Risk • Feb 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (₩7.0b revenue, or US$4.7m).
お知らせ • Jan 23Anterogen.Co.,Ltd. announced that it expects to receive KRW 5.0000314 billion in fundingAnterogen.Co.,Ltd. announced a private placement of 274,727 common shares at a price of KRW 18,200 for gross proceeds of KRW 5,000,031,400 on January 23, 2025. The transaction includes participation from Horizon Flowkai Venture Fund subscribed for 241,759 shares and Horizon Flow No. 1 PEF subscribed for 32,968 shares. The transaction has been approved by the board of directors of the company. The payment date of the transaction is January 31, 2025. The transaction is subject to lockup for one year from the date of deposit. The company will issue shares of par value of KRW 500 per share through third party allocation capital increase method.
New Risk • Nov 14New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩140.4b (US$100.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.6% per year over the past 5 years. Minor Risks Revenue is less than US$5m (₩6.7b revenue, or US$4.7m). Market cap is less than US$100m (₩140.4b market cap, or US$100.0m).
New Risk • Aug 05New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩130.4b (US$95.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.4% per year over the past 5 years. Minor Risks Revenue is less than US$5m (₩6.5b revenue, or US$4.8m). Market cap is less than US$100m (₩130.4b market cap, or US$95.6m).
New Risk • Apr 17New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩137.4b (US$99.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.9% average weekly change). Revenue is less than US$5m (₩6.5b revenue, or US$4.7m). Market cap is less than US$100m (₩137.4b market cap, or US$99.3m).
分析記事 • Apr 04Does Anterogen.Co.Ltd (KOSDAQ:065660) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
New Risk • Apr 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Revenue is less than US$5m (₩6.5b revenue, or US$4.8m).
New Risk • Feb 05New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩132.3b (US$99.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Revenue is less than US$5m (₩6.3b revenue, or US$4.7m). Market cap is less than US$100m (₩132.3b market cap, or US$99.4m).
New Risk • Oct 06New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩131.3b (US$97.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risks Revenue is less than US$5m (₩6.2b revenue, or US$4.6m). Market cap is less than US$100m (₩131.3b market cap, or US$97.5m).
Reported Earnings • May 16First quarter 2023 earnings released: EPS: ₩4.00 (vs ₩273 loss in 1Q 2022)First quarter 2023 results: EPS: ₩4.00 (up from ₩273 loss in 1Q 2022). Net income: ₩37.4m (up ₩2.65b from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 03Full year 2022 earnings released: ₩706 loss per share (vs ₩59.00 loss in FY 2021)Full year 2022 results: ₩706 loss per share (further deteriorated from ₩59.00 loss in FY 2021). Net loss: ₩6.84b (loss widened ₩6.28b from FY 2021). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 16Third quarter 2022 earnings released: ₩155 loss per share (vs ₩43.00 loss in 3Q 2021)Third quarter 2022 results: ₩155 loss per share (further deteriorated from ₩43.00 loss in 3Q 2021). Net loss: ₩1.51b (loss widened 274% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
お知らせ • Mar 09Anterogen.Co.,Ltd. announced that it has received KRW 16 billion in funding from Shinhan Venture Investment Co, Ltd., NH Investment & Securities Co., Ltd., Investment Arm, SL InvestmentOn March 8, 2021, Anterogen.Co.,Ltd. (KOSDAQ:A065660) closed the transaction. The company issued round 5 unregistered unguaranteed unsecured convertible bonds.
お知らせ • Feb 09Anterogen.Co.,Ltd., Annual General Meeting, Mar 19, 2021Anterogen.Co.,Ltd., Annual General Meeting, Mar 19, 2021, at 09:00 Korea Standard Time.
分析記事 • Feb 05Health Check: How Prudently Does Anterogen.Co.Ltd (KOSDAQ:065660) Use Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Is New 90 Day High Low • Dec 20New 90-day high: ₩55,200The company is up 4.0% from its price of ₩53,300 on 21 September 2020. The South Korean market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 7.0% over the same period.
分析記事 • Dec 14Does Anterogen.Co.Ltd's (KOSDAQ:065660) Share Price Gain of 25% Match Its Business Performance?It hasn't been the best quarter for Anterogen.Co.,Ltd. ( KOSDAQ:065660 ) shareholders, since the share price has fallen...
Reported Earnings • Nov 18Third quarter 2020 earnings released: EPS ₩110Third quarter 2020 results: Net income: ₩983.9m (up ₩1.46b from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 87% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Oct 22New 90-day low: ₩46,550The company is down 30% from its price of ₩66,800 on 24 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 10.0% over the same period.